Navigation Links
Moffitt Cancer Center researchers design small molecule to disrupt cancer-causing protein
Date:3/25/2013

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have developed a small molecule that inhibits STAT3, a protein that causes cancer. This development could impact the treatment of several tumor types, including breast, lung, prostate and others that depend on STAT3 for survival.

The study appeared in the Jan. 15 online issue of Cancer Research, a publication of the American Association for Cancer Research.

"STAT3 has been associated with poor prognosis and resistance to chemotherapy in patients with cancer," explained Said M. Sebti, Ph.D., chair of the Drug Discovery Department at Moffitt. "Two STAT3 molecules need to bind to each other, a process called dimerization, to cause malignancy. We developed a small molecule called S3I-1757 to prevent dimerization by disrupting STAT3-STAT3 binding. Once disrupted, STAT3's ability to help cancer cells survive, grow and invade is neutralized."

"Activated STAT3 contributes to cancer at several levels," said study co-author Nicholas J. Lawrence, Ph.D., senior member of Moffitt's Drug Discovery Department. "It triggers the uncontrolled proliferation, invasion and spread of cancer cells. That makes STAT3 an attractive target for drug discovery and therapy."

STAT3 was first found to be involved in malignant transformation in 1995, but researchers have been unable to develop an inhibitor for the protein. In part, the challenge stemmed from the fact that STAT3-STAT3 binding is a protein-protein interaction involving a large surface area, difficult to target with drug-like small molecules.

The researchers, who had been working on finding an inhibitor for STAT3-STAT3 dimerization for some time, recently overcame that challenge and demonstrated in laboratory studies that S31-1757 was effective in neutralizing STAT3's activity.

"We used several approaches to demonstrate that S31-1757 is able to inhibit malignant transformation by its ability to inhibit the STAT3 function," Sebti said. "These included targeting the ability of STAT3 to bind itself."

Their findings will be presented at the annual AACR meeting in April in Washington, D.C.


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Genetic risk strategies needed for young, black, female breast cancer patients, Moffitt study shows
2. Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
3. Cancer doesnt change young girls desire to have children, Moffitt Cancer Center study shows
4. Surgery and radiation improve survival for metastatic gastric cancer patients, Moffitt study shows
5. Moffitt researchers say silencing of retinoblastoma gene regulates differentiation of myeloid cells
6. Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer
7. Moffitt Cancer Center researchers develop automated breast density test linked to cancer risk
8. Tumor cells engineer acidity to drive cell invasion, Moffitt Cancer Center researchers say
9. New drug improves survival in multiple myeloma relapse, Moffitt Cancer Center researchers say
10. Moffitt study shows smoking cessation more successful for cancer patients who quit before surgery
11. Hispanics leery of health care providers, often avoid cancer screenings, Moffitt study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... Since ... the 21st Century Cures Act in the US, Nocimed has been marketing its ... Using images from existing MRI equipment to perform MR spectroscopy, NociScan detects ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... Dental Implants welcome patients with missing teeth in Chattanooga, TN for customized full ... a periodontist in as little as one day, providing a permanent tooth replacement ...
(Date:9/17/2019)... ... 2019 , ... Lubin Austermuehle, P.C. will be one of the ... be held at Found Kitchen and Social House in Evanston on Monday, October 7 ... Neurodevelopmental Disorder, a rare condition that results from changes to the GRIN2B gene. The ...
(Date:9/17/2019)... ... September 17, 2019 , ... Genomenon ... with the goal of providing resources to assist researchers and encourage pharmaceutical companies ... disease causing abnormal iron deposits in the brain. , BPAN Warriors is ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... Open House day on Pacifica's Lambert Campus, 249 Lambert Road, Carpinteria, CA. ... the Humanities, Clinical Psychology, Counseling Psychology, and Mythological Studies. Program Faculty will ...
Breaking Medicine News(10 mins):
(Date:9/17/2019)... EVANSTON, Ill. (PRWEB) , ... September 17, 2019 , ... ... grant from the Gordon and Betty Moore Foundation to launch the DxQI Seed Grant ... test interventions aimed at improving diagnostic quality and reducing harm from diagnostic error. ...
(Date:9/14/2019)... (PRWEB) , ... September 13, 2019 , ... ... of teledentistry services for employers, became the first commercial teledentistry practice in the ... award-winning startup with other hub entrepreneurs, company leaders, innovators and industry experts next ...
(Date:9/14/2019)... ... ... The Allergenic Products Advisory Committee of the Food and Drug Administration (FDA) met today ... a standardized oral immunotherapy (OIT) product for peanut allergy. The brand name is expected ... would require a Risk Evaluation and Mitigation Strategy (REMS) to be developed to help ...
Breaking Medicine Technology: